Palexia® SR (tapentadol) HCP Survey
To help us understand the relevance and impact of the content which has been shared with you we would be grateful if you can answer five short questions for us. This should take you no more than 5 minutes to complete and will really help us optimise our content.

For information on how your personal data will be processed can be found in our privacy notice here: https://www.grunenthal.co.uk/en-gb/footer-links/privacy-statement


    • It is critical to set and track time-bound and person-centred functionality goals, rather than relying on clinical observations only.
      Strongly desagree
      Neither agree nor disagree
      Strongly agree
      Don't know


    • I find it easy to set and track time-bound and person centred functional goals
      Strongly desagree
      Neither agree nor disagree
      Strongly agree
      Don't know


    • It is critical to set and track time-bound and person-centred functionality goals, rather than relying on clinical observations only.

      The content...
      ...had no impact on my agreement with this statement
      ...made more likely to agree with this statement
      ...made more likely to disagree with this statement



    • I find it easy to set and track time-bound and person centred functional goals.

      The content...
      ...had no impact on my agreement with this statement
      ...made more likely to agree with this statement
      ...made more likely to disagree with this statement


  4. Not at all likely
    Disabled text
    Extremely likely





Statement regarding the responsible use of opioid-based medicines

Grunenthal manufactures Palexia SR (tapentadol) and Tramadol. To ensure appropriate use of their medications Grunenthal have developed the following guidance:
General considerations for the management of pain with any medication that contains an opioid mechanism of action

The following general aspects should be considered
  • An individualized, patient-centered approach for the diagnosis and treatment of pain is essential to establish a therapeutic alliance between patient and clinician.
  • Consider patient variables that may affect opioid dose for each patient prior to opioid use (1)
  • In patients with acute pain e.g. post-surgery pain, the use of medication should be for the shortest necessary time (1)
  • All patients should be carefully selected, abuse risk factors evaluated and regular monitoring and follow-up implemented to ensure that opioids are used appropriately (3-4) and in alignment with treatment goals (pain intensity and functionality) as agreed with the patient (3-4)
  • Patients should be made aware of the potential side effects of opioids and the potential for developing tolerance, dependence and addiction (3-4).
  • It is important to optimally use multimodal, non-opioid approaches in acute and chronic pain before escalating to opioids or in conjunction with opioid therapy (1)
  • Addiction is possible even when opioids are taken as directed. The exact prevalence of abuse in patients treated with opioids for chronic pain is difficult to determine (5)
  • Regular clinical reviews are required for long-term opioid treatment to assess pain control, impact on lifestyle, physical and psychological well-being, side effects and continued need for treatment (2)
  • Any long term treatment with opioids should be monitored and re-evaluated regular incl. tapering down the dose or discontinuing treatment (3-4)
  • Signs of opioid use disorder should be monitored and addressed (3-4)
  • Patients and the general public can benefit from clear educational materials and awareness interventions to support the responsible use of opioids (6)

  1. DHHS Pain Management Best Practices Inter-Agency Taskforce Report May 2019
  2. O’Brien T et al. Eur J Pain 2017;21:3-192
  3. Faculty of Pain Medicine, Opioids Aware
    https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware Accessed September 2019
  4. Kosten TR et al, Scie Pract. Perspect 2002;1:13-20
  5. Rosenblum A et al Exp. Clin. Psychopharmacol. 2008;16(5):405-416
  6. OECD Health Policy. Addressing Problematic opioid use in OECD Countries May 2019 http://www.oecd.org/health/addressing-problematic-opioid-use-in-oecd-countries-a18286f0-en.htm
Job Number: M-PLX-UK-08-21-0020
Date of preparation: August 2021